AbbVie's Third-Quarter 2025 Financial Performance Released: Key Insights and Expectations

AbbVie Reports Its Financial Results for the Third Quarter 2025

On October 31, 2025, AbbVie (NYSE: ABBV) announced its financial performance for the third quarter ending September 30, 2025. The report revealed a diluted earnings per share (EPS) of $0.10 on a GAAP basis, marking a significant decline of 88.6%. The adjusted diluted EPS stood at $1.86, which is down by 38.0%. This adjustment reflects an unfavorable impact of $1.50 per share related to acquired IPRD and milestones expense.

For the third quarter, AbbVie reported a net revenue of $15.776 billion, showing a robust increase of 9.1% on a reported basis or 8.4% operationally. This increase was driven predominantly by growth in its immunology portfolio, which brought in $7.885 billion, an impressive rise of 11.9% on a reported basis, or 11.2% operationally. Notably, the new entries in the immunology portfolio, Skyrizi and Rinvoq, contributed significantly to this increase with net revenues of $4.708 billion and $2.184 billion, respectively.

Despite the upward trend in these areas, AbbVie did experience declines in some of its product lines. The revenue from Humira experienced a dramatic decline of 55.4%, now totaling $993 million. In contrast, the neuroscience segment performed strongly, tallying up $2.841 billion, which represents a 20.2% increase from the previous year. This includes Vraylar and Botox therapeutic, which posted solid revenue increases.

In terms of the oncology segment, AbbVie saw a slight dip in global net revenues of $1.682 billion, which is a decrease of 0.3%. This decrease came despite an increase in revenue from Venclexta, a notable product in its oncology portfolio.

Looking at their aesthetics portfolio, AbbVie revenue dropped by 3.7%, concluding the quarter at $1.193 billion, primarily impacted by a decrease in Botox Cosmetic sales, which fell to $637 million.

AbbVie has adjusted its earnings forecast for the full year of 2025, increasing the guidance range from $10.38-$10.58 to $10.61-$10.65 per share. This includes the noted unfavorable impact from the IPRD and milestones expenses, highlighting not only the company’s proactive approach to managing financial forecasts but also their confidence in future performance.

Moreover, AbbVie has declared a 5.5% dividend increase, starting from February 2026, demonstrating their commitment to shareholder value amidst fluctuating revenue streams.

In his remarks, AbbVie CEO Robert A. Michael highlighted the company's significant momentum and ongoing advancement in key therapeutic areas, primarily pointing towards an innovative pipeline that promises sustainable growth.

Moreover, AbbVie announced it has secured FDA approval for Rinvoq concerning the treatment of ulcerative colitis, enhancing their product offerings in gastrointestinal diseases. Additionally, the announcement of a completed acquisition of Capstan Therapeutics, gives the company access to a pioneering liposomal therapy candidate, further diversifying its portfolio.

The quarterly performance reflects a mixed bag of results across different segments, yet AbbVie’s strategic actions indicate a focused effort on growth and shareholder returns. The upcoming trajectory will be key as the company navigates through its pipeline advancements and product launches. Investors are undoubtedly keen to monitor how these developments unfold in the following quarters, especially in light of their increasing market share in the immunology and neuroscience spaces.

Conclusion

AbbVie’s financial results for Q3 2025 underline challenges but also shine a light on significant growth opportunities through key portfolio segments and strategic initiatives aimed at both innovative development and enhancing shareholder value. The upcoming quarters will be critical as the market evaluates how effectively AbbVie can translate this momentum into sustained financial health and growth.